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Abstract
Background: Currently available tools cannot be used to distinguish between sub-species of the M. tuberculosis
complex causing latent tuberculosis (TB) infection. M. africanum causes up to half of TB in West- Africa and its
relatively lower progression to disease suggests the presence of a large reservoir of latent infection relative to M.
tuberculosis.
Methods: We assessed the immunogenicity of the TbD1 region, present in M. africanum and absent from
“modern” M. tuberculosis, in an ELISPOT assay using cells from confirmed M. africanum or M. tuberculosis infected TB
patients without HIV infection in the Gambia.
Results: Antigens from the TbD1 region induced IFNg responses in only 35% patients and did not discriminate
between patients infected with M. africanum vs. M. tuberculosis, while PPD induced universally high responses.
Conclusions: Further studies will need to assess other antigens unique to M. africanum that may induce
discriminatory immune responses.
Background
An estimated third of the world’s population is latently
(asymptomatically) infected with M. tuberculosis,o f
whom 5-10% will progress to TB disease in their life-
time, with higher rates of progression in immune com-
promised people [1]. Latent infection can be diagnosed
with the tuberculin skin test, or more recently with
interferon gamma release assays using M. tuberculosis
specific antigens ESAT-6 andC F P - 1 0[ 2 ] .T h e s ea n t i -
gens are present in members of the M. tuberculosis
complex, except for the vaccine strain M. bovis BCG [3],
M. microti and the Dassie bacillus.
Recent data suggest that M. africanum has a relatively
large reservoir of latent infection that supports the 38%
prevalence of active disease despite a lower rate of
progression.
Better characterization of the immune responses lead-
ing either to containment or progression of latent TB
infection to disease by M. africanum or M. tuberculosis
requires diagnosis of these organisms at the latent stage
of infection. During latent TB infection, the bacterial
load is estimated to be low, and the location of the persis-
tent bacteria is unknown. Molecular genotyping methods
rely on the isolation of bacterial DNA, which is currently
not possible from patients with latent TB infection.
Nevertheless, the persistent bacteria induce an immune
response that can be assessed in the periphery [1].
The TbD1 region is present in M. africanum but
absent in “modern” M. tuberculosis [3]. M. bovis has not
yet been isolated from humans or bovines in the Gam-
bia [4,5], and “ancient” M. tuberculosis causes only 3.4%
of TB in the Gambia [6].
T h e r e f o r ew eh y p o t h e s i z e dt h a tar e s p o n s et oT b D 1
antigens should be relatively specific for M. africanum,
which could subsequently be used to determine the pre-
valence of latent infection with M. africanum. We tested
the sensitivity and specificity of these TbD1 antigens in
an ex-vivo IFN-g ELISPOT assay in TB cases infected
with M. africanum or M. tuberculosis.
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After informed consent, adult patients with smear posi-
tive TB were recruited in an ongoing TB Case Contact
study in the Gambia and offered Voluntary Counseling
and Testing for HIV as described previously [2]. This
study was approved by the joint Gambian Government/
MRC ethics committee and by the IRB from New York
University. HIV infected patients were excluded from
this analysis.
Synthetic peptides
Antigens were prepared from TbD1, a region missing
from “modern” M. tuberculosis and present in M. africa-
num and M. bovis [3]. TbD1 contains 2 genes, mmpL6
and mmpS6, of which mmpL6 was prepared as 2 sepa-
rate peptides, mmpL6-C and mmpl6-N. Due to con-
straints in the number of cells, we initially screened
these two peptides from mmpL6 in separate wells in
ELISPOT, and later selected mmpL6-C together with
mmpS6 as test antigens.
RD-1 and TbD1 antigens in ex vivo IFNg ELISPOT
We used an ex vivo ELISPOT technique to enumerate
frequencies of circulatory IFNg -producing T cell
r e s p o n s e sa ss h o w np r e v i o u s l y[ 2 ] .B r i e f l y ,p e r i p h e r a l
blood mononuclear cells (PBMC) were isolated from 15
ml heparinized whole blood and resuspended in RPMI-
1640 culture media supplemented with100 IU/ml peni-
cillin, 100 μg/ml streptomycin, 5% heat-inactivated AB
human serum (Sigma), and 2 mM L-glutamine. The
cells were then plated in duplicate at 2 × 10
5 per well,
and cultured for 18 h at 37°C with the following anti-
gens: medium alone, ESAT-6 peptide pool (EP, 2.5 μg/
ml), CFP-10 peptide pool (CP, 2.5 μg/ml) [2,7,8], ESAT-
6/CFP-10 fusion protein (FP, 5 μg/ml), PPD-tuberculin
(PPD-T [M. tuberculosis, RT49; Statens serum Institut,
Copenhagen, Denmark], 20 μg/ml), peptides corre-
sponding to TbD1 antigen (prepared by C. Franken, 10
μg/ml), and PHA (Sigma-Aldrich, 5 μg / m l )t h a ts e r v e d
as a positive control. The ELISPOT plates were devel-
oped following the manufacturer’s instructions and spot
forming units (SFU) were scored with an automated
ELISPOT counter (AID-GmBH, Strasbourg, Germany).
A positive response (cut-off) was recorded if SFU were
≥ 8 spots above background and there were twice as
m a n ys p o t sa sn e g a t i v ec o n t r o lw e l l s .D a t aw e r e
excluded if PHA positive control wells were <150 spots
[7-9].
Laboratory isolates and genotyping
All TB cases submitted sputum for conventional myco-
bacteriology, including Acid Fast smears and cultures in
liquid and solid media as described previously [6]. By
genotyping the isolates from these patients using spoli-
gotyping [10], we classified the patients as infected with
M. africanum or M. tuberculosis [5].
Statistical analysis
We used Stata software (version 10; Stata-Corp) and
performed the non-parametric Mann-Whitney test to
compare continuous variables, considering P <0 . 0 5a s
statistically significant.
Results
Patient and isolate characteristics
We enrolled 81 TB patients, of whom 74 (91%) agreed
with HIV testing, including nine who tested positive
(12.2%, eight with HIV-1 and one with HIV-2). Of the
65 HIV negative TB patients, one patient had uninter-
pretable ELISPOT results, two did not have a genotyped
bacterial isolate, and 62 (77%) patients were included in
the analysis. Both mmpL6-C and mmpL6-N peptides
were tested in 24 patients, while mmpL6-C peptide
alone was tested in combination with the mmpS6 pep-
tide in 38 patients. TB disease was caused by M. africa-
num in 21 (34%) of the patients, with the remainder due
to M. tuberculosis, including 3 (4.8%) “ancient” M.
tuberculosis isolates with intact TbD1 region.
Immunogenicity of M. africanum specific peptides
The mmpL6-C peptide induced IFNg responses in 19% of
M. africanum infected cases, the mmpL6-N peptide in
17%, and the mmpS6 peptide in 20%. The proportion who
responded to any of the three TbD1 antigens was similar
between M. africanum infected patients and M. tuberculo-
sis infected patients (respectively 33% and 37%, p = 0.80).
Equal numbers of patients infected with M. africanum and
with M. tuberculosis responded to PPD (respectively 95%
and 90%, p = 0.49), whereas responses to ESAT-6, CFP-10
and ESAT-6/CFP-10 fusion protein tended to be lower in
M. africanum infected patients (Figure 1).
Of the three patients infected with “ancient” M. tuber-
culosis, one responded to TbD1 antigens and two did
not. The results did not change significantly with the
inclusion or exclusion of these cases as M. tuberculosis-
infected in the analysis.
Discussion
To our knowledge, this study is the first attempt at
uncovering TB sub-species specific T cell responses in
the natural human host. Our findings suggest that the
antigens prepared from TbD1 do not induce a robust T
cell response in humans. Among the responders, there
was moreover no difference in TbD1 recognition
between the proportion of patients infected with “mod-
ern” M. tuberculosis, which lacks the TbD1 region, and
the proportion infected with M. africanum,w i t ha n
intact TbD1 region. Lastly, we identified a trend towards
attenuated immunogenicity of ESAT-6 and CFP-10 in
M. africanum infected TB cases, on which we reported
previously [11].
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host recognition of these antigens, or due to the fact
that the host response includes cytokines other than
IFNg or B cell rather than T cell responses. Indeed,
mmpL6 is a putative transmembrane transport protein
[12] and may induce a B cell response against its extra-
cellular tail.
Although we did not identify instances of dual infec-
tion from the cultured sputum samples, the presence of
dual infection could explain the inability of the TbD1
antigens to discriminate between those diseased with M.
africanum from M. tuberculosis. Undetected dual infec-
tion in TB patients could occur when one organism was
maintained in latency while the other caused TB disease,
or when both organisms partook in active TB disease,
but one organism outgrew the other in culture. The lat-
ter can be addressed by genotyping the isolates with
species-specific primers using DNA extracted from spu-
tum samples.
The M. africanum whole genome sequencing project
is near completion, which will facilitate the search for
other discriminatory antigens unique to M. africanum.
The TbD1 region, shared by M. africanum and M.
bovis, is the only region identified in the M. bovis gen-
ome that is absent from M. tuberculosis, so our findings
may also inform veterinary research directed at
distinguishing M. bovis-v s“modern” M. tuberculosis
specific responses in latently infected cows.
Conclusions
In conclusion, assessment of the prevalence of TB
latency with one or more different sub-species within
the M. tuberculosis complex will depend on the detec-
tion of specific host responses, due to inability to extract
mycobacterial DNA from latently infected individuals.
The TbD1 region, which is absent in “modern” M.
tuberculosis and present in M. africanum and M. bovis,
does not induce a discriminatory IFNg Tc e l lr e s p o n s e
in TB patients in the Gambia. Further studies will need
to assess whether TbD1 induces B cell responses, which
would facilitate assessment of the prevalence of latent
infection with distinct sub-species. Alternatively, the
whole genome sequence may reveal other antigens
unique to M. africanum that may induce T cell- and/or
B cell responses.
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